Furmonertinib and Bevacizumab Tackle Resistant Leptomeningeal Metastasis
In the rapidly evolving landscape of targeted cancer therapies, the treatment of leptomeningeal metastasis (LM) remains a formidable challenge. A groundbreaking comment published recently in the British Journal of Cancer by Chang,...
Read moreDetails

